Phone Number
(800) 210-7017
(800) 210-7017
Anticoagulant and activator choices are the two pharmacological levers that decide what kind of clinical signal your finished PRP can actually deliver. The chemistry starts working the moment whole blood hits the tube and keeps shaping outcomes all the way through injection, so treating these as small protocol details is one of the fastest ways to compromise an otherwise sound treatment plan.
ACD-A paired with mild or absent exogenous activation is the dominant pairing for orthobiologic and tendon work, while thrombin-driven activation remains preferred for hemostatic and surgical sealant applications.
Treating these four agents as interchangeable is one of the most expensive mistakes a new PRP practitioner can make. The chemistry that makes EDTA perfect for a CBC tube is the same chemistry that turns it into platelet poison the moment you try to spin it for therapeutic use.
| Anticoagulant | Mechanism | PRP Suitability |
|---|---|---|
| ACD-A | Citrate chelation plus dextrose fuel | Gold standard, pH stable, ~1:9 ratio |
| Sodium citrate | Citrate chelation, no dextrose | Acceptable, drifts alkaline, faster viability loss |
| Heparin | Inhibits thrombin, leaves calcium free | Contraindicated, triggers premature aggregation |
| EDTA | Aggressive calcium chelation | Contraindicated, irreversible membrane damage |
ACD-A is the only anticoagulant that combines gentle calcium chelation with a metabolic substrate to keep platelets functional through the full processing window.
Platelet activation is a tightly choreographed signaling event that turns a quiet disc-shaped cell into a granule-releasing effector in seconds. Every trigger you’ll use clinically converges on the same intracellular calcium spike, but the path the cell takes to get there changes both the timing and the durability of the growth factor signal.
Thrombin-driven PAR receptor activation releases most alpha-granule cargo within five to ten minutes, while collagen-driven endogenous activation paces release over hours to days because granule fusion is gated by ongoing tissue contact.
Choosing between calcium chloride and thrombin is one of the most consequential decisions in your protocol design, because they represent fundamentally different philosophies of when and how fast you want your signal delivered. One gives you a workable window measured in minutes; the other gives you seconds before the product is locked.
| Parameter | Calcium Chloride (10% w/v) | Thrombin |
|---|---|---|
| Mixing Ratio | ~1:10 activator to PRP | ~1:10 activator to PRP |
| Clot Formation | Seconds to minutes, loose and slow | Seconds, dense and immediate |
| Release at 10 min | ~30 to 40% over first hour | >70% of alpha-granule cargo |
| Total Release Window | Sustained out to 24+ hours, days as fibrin degrades | Flattens by 60 to 90 minutes |
| Best Use | Tendon, ligament, intra-articular | Surgical sealing, hemostatic gels |
A small dose of thrombin combined with calcium chloride produces an intermediate kinetic profile that captures thrombin’s potent activation while preserving some sustained release from the fibrin matrix.
Recovery rate isn’t just a vanity metric; it tells you what percentage of the platelets you drew actually make it into the syringe that touches the patient. The single biggest reason ACD-A wins on this measurement is that it carries its own fuel for the cells while they wait to be spun.
ACD-A’s dextrose component buffers metabolic decline and counteracts alkaline drift, giving your workflow real tolerance for the slow days when a draw sits longer than planned.
Activation timing is one of the most practitioner-dependent variables in PRP delivery, and small differences in when you add activator can change the clinical effect of an otherwise identical product. Get the timing wrong and you’ll either inject inert plasma or end up with a clot stuck in your needle.
Unactivated PRP is the standard for epicondylitis, plantar fasciitis, knee osteoarthritis, and rotator cuff tendinopathy because the syringe stays fluid and activation happens precisely where the product is needed.
Every anticoagulant and activator carries a risk profile, and a couple of those risks are serious enough that they’ve reshaped modern best practice. The worst of them aren’t theoretical; they’ve shown up in real patients, real coagulopathies, and real published case series.
Bovine thrombin should be replaced with recombinant human or autologous thrombin whenever possible, because the antibody response can outlast the treatment by months and cause bleeding complications unrelated to PRP itself.
The in vitro data on growth factor release is detailed enough that you can predict the kinetic curve of almost any protocol before you draw a tube. What surprises most clinicians is that total signal delivered may be roughly similar across activation methods; what differs is when the signal arrives and how long it lingers.
Platelet concentration multiplies total growth factor output proportionally regardless of activation method, but the release kinetic shape is dictated almost entirely by the activator you choose.
Clinical indication is the single most important factor in choosing your anticoagulant and activator pairing, because the temporal and physical demands of each target tissue are wildly different. What’s perfect for a knee joint is wrong for a diabetic foot ulcer, and what works for a facial rejuvenation will fail in an extraction socket.
Leukocyte-rich PRP amplifies the initial inflammatory response when activated, which helps chronic non-healing wounds but should be avoided for intra-articular use where synovial irritation is the failure mode.
FDA oversight of PRP kits runs through the 510(k) clearance pathway under the device framework, with kits sitting in Class II. The clearance covers the tubes, separation gels, draw needles, and the named anticoagulant, but the rules get murkier the moment you add an activator at the bedside.
Combining PRP with stem cells, culturing platelets, or other aggressive manipulations can push the product out of the HCT/P exemption and into full biologic regulation, where the burden multiplies dramatically.
The headline finding from the comparative literature is that activation strategy matters less than many practitioners assume for most musculoskeletal indications, while it matters significantly more for wound care and surgical applications. The methodological noise is high, and protocol heterogeneity confounds almost every direct comparison you’ll read.
| Indication | Activated PRP | Non-Activated PRP |
|---|---|---|
| Knee osteoarthritis | Similar 6 and 12 month outcomes | Slight edge on early pain and function |
| Lateral epicondylitis, rotator cuff | Not a primary outcome driver | Not a primary outcome driver |
| Diabetic foot ulcers, pressure injuries | Clear benefit from thrombin-activated gel | Inferior, lacks scaffold structure |
| Spinal fusion, dental implants | Clear benefit, rapid clot and immediate signaling | Suboptimal for surgical fields |
Trials reporting a thrombin activation benefit are often confounded by higher platelet concentration in the same arm, so weight protocol-consistent studies and covariate-adjusted meta-analyses far more heavily than headline conclusions.
